PuraMed BioScience® (OTCBB: PMBS) Reports Increased Revenue From Sales of LipiGesic® M

Orlando, FL 2/16/12 (StreetBeat) -- PuraMed BioScience®, Inc. (OTCBB: PMBS), the producer of over-the-counter medicinal and healthcare products, announced today its financial results for the second quarter ended December 31, 2011 in conjunction with the publication of its quarterly 10Q SEC filing.

PuraMed BioScience reported net revenues for the three months ended December 31, 2011 of $608,676 compared to $1,869 for the same three month period ended December 31, 2010. The increase in revenue was primarily generated from initial orders of their unique, non-prescription migraine product, LipiGesic® M, by Walgreens, the #1 drug-store chain in the country.

For this same period, PuraMed BioScience also reported gross profits of $490,581 compared to $1,116 for the same three month period ended December 31, 2010. As a result of the rapid expansion into 15,000 stores and the associated increased advertising costs, the Company had a negative working capital (current assets minus current liabilities), as of December 31, 2011. The Company is actively seeking additional capital to accomplish its planned business strategy and support its projected expenses.

"The revenue received from the successful roll-out of our product at national retail drug stores will play a key role in fulfilling our capital needs," said Sue Baacke, CFO of PuraMed BioScience. "The earnings demonstrated during the last quarter of 2011, indicate the Company's ability to satisfy operating expenses associated with the roll-out of LipiGesic M. As liabilities are addressed, we will continue to build equity for our shareholders as we expand the market presence of LipiGesic M."

According to PuraMed BioScience CEO Russell Mitchell, "This quarter represents an important milestone for PuraMed as it is the first quarter which we were able to successfully show income from operations. It should be noted that this quarter only reflects initial revenue from Walgreens and we anticipate experiencing continued growth of revenue with the addition of CVS and additional retail opportunities worldwide."

LipiGesic M is a clinically tested homeopathic medication that has been shown to be highly effective and safe as a treatment formigraines. This sublingual formulation is now available as an over-the-counter product in major retail drug stores nationwide.

Mitchell added, "LipiGesic M's presence on retail shelves will also help fill the void left by recent OTC migraine medication recalls. We remain confident that continued execution of our business strategy to generate an increase of sales will result in increased value for our shareholders."

StreetBeat Disclaimer

Distributed by Viestly

PuraMed BioScience (OTCBB: PMBS) Migraine Treatment Now Available at CVS, the 2nd Largest Drug Chain in the United States

Northern, WI 1/25/12 (StreetBeat) -- PuraMed BioScience, Inc. (OTCBB: PMBS) announced today that LipiGesic M, their clinically proven effective and safe, all natural product for the treatment of migraine headaches, is now available for purchase at CVS, the 2nd Largest Drug Chain in the United States. With the addition of over 7,000 CVS locations, LipiGesic®M is now available in approximately 15,000 stores nationwide.

"We are pleased to now have our LipiGesic®M product available in both the #1 and #2 Drug Chain stores in the United States. Between the nearly 8,000 Walgreens and 7,000 CVS locations nationwide, we believe our product is gaining the exposure needed to generate significant revenue," stated Russ Mitchell, CEO of PuraMed BioScience.

PuraMed BioScience, Inc. anticipates announcing additional distribution in chain drug stores in the near future.

StreetBeat Disclaimer

Distributed by Viestly

PuraMed BioScience Inc. Announces Migraine Medicine Purchase Orders From CVS Pharmacy

Tallahassee, FL 12/6/11 (StreetBeat) --PuraMed BioScience Inc. (OTCBB:PMBS) announced today that it has received an initial series of purchase orders for its new over-the-counter migraine medication, LipiGesic(R)M with the second largest chain drug retailer in the United States, CVS (NYSE:CVS). This follows a recent announcement that LipiGesic(R)M is now available nationwide at Walgreens, the largest chain of drug stores in the United States.

CVS has over 7,000 locations in the United States which will almost double the amount of stores that will carry their featured product, LipiGesic(R)M, bringing the total number of stores to over 14,700. "This is a very exciting time for our Company," said Russ Mitchell, CEO of PuraMed BioScience. "In just the past few months, we have been able to announce purchase orders with the #1 and #2 chain drug stores in the U.S. Adding 7,000 CVS stores nationwide will nearly double our national exposure and dramatically affect our ability to reach even more migraine sufferers. While we are elated to have achieved this impressive level of national distribution, we will continue to actively pursue additional retail opportunities worldwide."

PuraMed expects to ship product to CVS in the beginning of January 2012 and anticipates it will begin to appear on shelves sometime around the end of January.

In addition to purchase orders of LipiGesic(R)M from both Walgreens and CVS, PuraMed also recently announced that three top headache researchers performed a study of LipiGesic(R)M that was published in the top-tier medical journal, Headache Volume 51, Number 7, July/August 2011. This study demonstrated that the product was highly effective and recommended LipiGesic(R)M as a first line treatment for migraines to the medical community.

PuraMed BioScience, Inc. plans to provide more information as it becomes
available.

StreetBeat Disclaimer

Distributed by Viestly